Ultherapy PRIME vs Ultherapy: What Actually Changed?
Written by Ultherapy in Seoul editorial team · Editorially updatedUltherapy PRIME is documented as a newer console for the Ulthera System, not as a new clinical outcome claim. In the US FDA's 2024 510(k) record, PRIME and the earlier predicate use identical ultrasound signal energy and treatment guidelines, with the same intended use, indications, main components and imaging mode. The documented changes concern the console design, display, interface and updated hardware. The FDA record does not show that PRIME produces a better clinical result.
Searches for “Ultherapy PRIME vs Ultherapy” often mix together three separate questions: whether the treatment changed, whether the operator experience changed, and whether patients should expect a better outcome. The public records answer the first two. They do not establish the third.
The documented differences at a glance
| Question | Ultherapy PRIME | Earlier Ulthera console |
|---|---|---|
| 510(k) summary comparison | Subject device in K233996 | Predicate device K180623 |
| Intended use and US indications | Same in the 510(k) summary comparison | Same in the 510(k) summary comparison |
| Ultrasound delivery | Identical signal energy and treatment guidelines | Identical signal energy and treatment guidelines |
| Main components | Console, handpiece and interchangeable transducers | Console, handpiece and interchangeable transducers |
| Imaging mode | Same mode for visualizing the treatment area and supporting transducer contact | Same mode for visualizing the treatment area and supporting transducer contact |
| Display listed in the 510(k) summary | 18.5-inch, 16:9, 1920 × 1080 | 15-inch, 4:3, 1024 × 768 |
| Console changes | Updated industrial design, interface, hardware and operating system | Earlier console design and system components |
| Evidence of better patient outcomes | Not established by K233996 | Not a superiority comparison |
Source: the 510(k) summary published in FDA's K233996, especially its device description and substantial-equivalence table on PDF pages 5–8.
What stayed the same
The 510(k) summary says PRIME and the predicate share the same intended use and US indications. It also says they use identical ultrasound signal energy and treatment guidelines, the same console-handpiece-transducer component structure, and the same imaging mode. Most directly, the 510(k) summary says the differences do not significantly affect clinical functionality or performance specifications.
That wording is the most useful answer for a prospective patient. PRIME modernizes how the system is presented and operated. The 510(k) record does not describe a new treatment mechanism or a clinically superior result. It also does not compare individual practitioners, treatment plans or patient outcomes.
What the PRIME console changes
The 510(k) summary documents a larger, higher-resolution display, a modernized graphical interface, updated hardware and a newer operating system. The manufacturer's PRIME product page also describes a tiltable capacitive touchscreen, an integrated work surface, quieter system sounds and faster ultrasound-image refresh. Those are product and workflow descriptions from the manufacturer. They should not be converted into a claim of better lifting, longer-lasting results, less pain or improved safety.
What the US FDA record means—and what it does not
K233996 is a US 510(k) clearance dated February 22, 2024. FDA determined that the modified Ulthera System was substantially equivalent to its legally marketed predicate for the indications stated in the record. A 510(k) clearance is not a premarket approval, and this US record does not establish clearance, licensing or permitted advertising claims in Korea or any other jurisdiction.
The performance section describes non-clinical software, usability, mechanical, electrical, packaging and ultrasound-output testing. It does not report a head-to-head patient trial of PRIME versus the earlier console. That is why the honest comparison stops at the documented system and workflow changes. For the treatment mechanism itself, see what Ultherapy is and how MFU-V works.
Questions to ask before booking
- Which Ulthera console will be used for my appointment?
- Who will assess me, plan the treatment and operate the system?
- How will the treatment area and goals be chosen for me?
- How will ultrasound visualization be used during treatment?
- Which benefits, limitations and possible adverse effects apply to my situation?
A console name cannot answer those questions on its own. If you are considering treatment in Seoul, the clinic's Ultherapy consultation overview explains its consultation-led process. This article does not state which console that clinic or any other provider currently operates; confirm the exact system directly before booking.
Frequently asked questions
Are Ultherapy PRIME and earlier Ultherapy the same treatment?
They are versions of the Ulthera System. In the 510(k) summary for K233996, PRIME and the predicate console have the same intended use and indications, identical ultrasound signal energy and treatment guidelines, the same main components, and the same imaging mode. PRIME changes the console, interface and supporting hardware.
Does Ultherapy PRIME produce better patient results?
The K233996 record does not establish better patient outcomes. The 510(k) summary says the console differences do not significantly affect clinical functionality or performance specifications. The manufacturer describes workflow and visualization updates, but those descriptions should not be read as proof of superior clinical results.
What is the US regulatory status of Ultherapy PRIME?
K233996 is a US 510(k) clearance, not a premarket approval. FDA found the modified Ulthera System substantially equivalent to its legally marketed predicate for the listed US indications. The record does not establish clearance in Korea or any other country.
How can I know which Ultherapy console a clinic uses?
Ask the provider to identify the console that will be used for your appointment. This page compares public product records and does not claim that any particular clinic operates PRIME or an earlier console.
Primary sources
- US Food and Drug Administration. K233996: Ulthera System (UC-1 Control Unit PRIME), decision letter and 510(k) summary. February 22, 2024.
- Merz Aesthetics / Ultherapy. Meet Ultherapy PRIME: official manufacturer product page for physicians. Used only for manufacturer-described interface and workflow features.
This comparison is general information. It does not identify the device used by a particular clinic and does not recommend a treatment for any individual.